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Despite overwhelming evidence of clinical efﬁcacy, the use and dose of betablockers in
elderly patients with chronic heart failure are often suboptimal. The underuse and
underdose of betablockers in elderly may reﬂect true intolerability in older patients with
comorbidities and with increased risk of side effects. Different betablockers may have
different side-effects because of different pharmacological properties. Difference between
betablockers use in the clinical practice and clinical trials might be explained by the fact
that the major large-scale betablockers trials enrolled younger patients. The highest
tolerability in elderly heart failure patients was reported for nebivolol. The tolerability of
nebivolol in older patients might be explained by its unique pharmacological properties.
& 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Chronic heart failure is an epidemic with high mortality,
morbidity and signiﬁcant quality of life impairment. Patients
with stable chronic heart failure (CHF) from ischemic and
non-ischemic etiology, reduced left ventricular ejection frac-
tion (LV EF) and mild to severe symptoms should be treated
with betablockers unless there is a contraindication. Beta-
blockers are also recommended in patients with chronic
heart failure and preserved LV EF [1]. Several, large, prospec-
tive, randomized, placebo controlled trials showed the clin-
ical beneﬁt of betablockers in patients with CHF and systolic
left ventricular dysfunction with consistent mortality and
morbidity reduction [2–7]. It was uncertain whether the
beneﬁts of betablockers (BBs) extended to older patients
because previous BB trials included CHF patients who were
younger (less than 80 years). Majority of patients with CHF in
the community are elderly, with almost half being 80 years
and older [8]. The underuse and underdose of BBs in the
elderly may reﬂect true intolerability in older patients with
comorbidities and with increased risk of side effects. Evi-
dence of BBs use in elderly heart failure patients is limited.Evidence of betablocker use in elderly
heart failure patients
Tolerability of betablockers in older patients with chronic
heart failure (CHF) was an objective of several studies. The
second Carvedilol Open-Label Assessment (COLA II) aimed to
evaluate the tolerability of BBs in 1030 subjects with chronic
heart failure (CHF) with age greater than 70 years [9]. Patients
with systolic CHF with left ventricular ejection fraction (LV
EFo40%) and NYHA classes II–IV were included in the study.
Tolerability of carvedilol was deﬁned as doseZ6.25mg twice
daily at the 6-month follow-up. Tolerability of carvedilol was
high: 80% of patients enrolled in COLA II tolerated carvedilol
and the tolerability was independent of gender and the
presence of ischemic etiology of heart failure. Difference in
tolerability between age ranges (70–75, 475–80 and480) and
other variables was tested by analysis of variance. Advanced
age and the presence of obstructive airway disease were
associated with lower tolerability while the presence of dia-
betes mellitus appeared to be a predictor of better tolerability.
This surprising result was explained by the lower percentage
of extreme elderly patients with diabetes receiving carvedilol.
Titration of carvedilol to the target recommended dose was
not the main objective of the COLA II study. The achieved dose
was 29–33 mg per day with age difference: patients aged 70–75
achieved mean dose 33.3 mg per day whereas patients older
than 80 years achieved mean dose 29.3 mg per day. There is
limited information about the titration of betablockers to
target dose in elderly CHF patients too.Titrations of betablocker to target in elderly
heart failure patients
Titration to target dose of different betablockers was the aim
of the CIBIS-ELD Study [10]. The objective of the CIBIS-ELDtrial (the Cardiac Insufﬁciency Bisoprolol Study in Elderly)
was to evaluate the difference in achieving the target dose of
carvedilol and bisoprolol. This was a randomized, double-
blind trial with the primary endpoint tolerability of betablockers
when used at recommended target doses in patients 65 years
or older with systolic CHF, LV EFr45% and NYHA classZ II,
betablocker naïve or on less than 25% of the recommended
target. The patients were seen every 2 weeks with a doubling
of previous dose, the target dose of bisoprolol was 10 mg
daily and for carvedilol 25 mg twice daily within 6 weeks with
a ﬁnal visit at 10 weeks. For patients weighing more than
85 kg, the target dose for carvedilol was 50 mg twice daily
within 8 weeks and ﬁnal visit at 12 weeks. The tolerability
was deﬁned as reaching the target dose. Secondary endpoints
were change in NYHA class, heart rate, blood pressure, LVEF
and parameters of diastolic function, distance in 6 min walk
test, forced expiratory volume (one second – FEV1) and quality
of life evaluation. The total number of 883 patients was
randomized. In total, 75.7% of the subjects with mean age
72.8 years did not reach the primary endpoint with no
difference between the bisoprolol group and the carvedilol
group. Bradycardia was the most common cause of titration
failure in the bisoprolol group whereas pulmonary adverse
events were the most common reason for titration failure in
the carvedilol group. There was no signiﬁcant difference
between the two groups in the incidence of worsening heart
failure, hospital admission, hypotension and mortality. Only
decrease in hemoglobin level was seen in the carvedilol
group, mainly in patients’ betablocker naïve at randomiza-
tion. Blood pressure decreased in both groups, NYHA, LV EF
and 6 min walk test distance improved with no difference
between bisoprolol and carvedilol groups. The CIBIS-ELD
study showed that only 24% (resp. 25%) of the elderly heart
failure subjects are able to reach target betablocker dose after
12 weeks titration (with dose doubling every 2 weeks as
recommended in the ESC guidelines). Multivariate analysis
showed that higher heart rate at baseline, BMI425 kg/m and
BB pre-treatment dose 25% were predictors of tolerability.
Older age and NYHA III–IV classes were associated with not
achieving the target dose. Different incidences of bradycardic
events (higher in the bisoprolol group) and pulmonary events
(higher in the carvedilol group) in the elderly patients with
CHF in the CIBIS-ELD trial cohort might be explained by the
different pharmacological properties of betablockers. Biso-
prolol is the selective β1 - adrenoreceptor blocker, carvedilol is
the non-selective α1-β1-β2 adrenoreceptor blocker. The CIBIS-
ELD trial showed that titration of BBs in elderly heart failure
patients is difﬁcult. The proportion of patients achieving
target doses should be higher than in the CIBIS-ELD trial
when comparing data from other clinical trials with similar
subjects (Table 1).
As shown in the table, the proportion of patients reaching
target bisoprolol dose in the Cardiac Insufﬁciency Bisoprolol
Study II (CIBIS II trial) was higher than that in the CIBIS-ELD
study (43% vs. 24%, but lower than that on placebo – 61%).
However, the mean age of the subjects in CIBIS II study was
lower than that in the CIBIS-ELD cohort (61 years vs. 73 years).
Titration scheme was somewhat different in these two trials:
doubling of the dose every 2 weeks (1.25 mg of bisoprolol or
placebo as a starting dose) in CIBIS-ELD, and increasing of
Table 1 – Proportion of patients achieving target beta-blockers dose in heart failure trials.
Study Number of patients Mean age Z70 age Beta-blocker % on target BB % on target placebo
SENIORS 2128 76 2128 Nebivolol 68 80
MERIT-HF 3991 64 1245 Metoprolol 64 82
CIBIS-II 2647 61 539 Bisoprolol 43 61
COPERNICUS 2289 63 NA Carvedilol 65 78
CIBIS-ELD 883 73 NA Carvedilol 25 NA
Z65 years Bisoprolol 24 NA
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in CIBIS II [3]. Not reaching the target bisoprolol dose was age
dependent in the CIBIS II trial too. Similarly, higher propor-
tion of patients were achieving target carvedilol dose in the
Carvedilol Prospective Randomized Cumulative Survival
Study (COPERNICUS) than that in the CIBIS-ELD trial (65%
vs. 25%) [5]. The COPERNICUS cohort was younger (mean age
was 63 years) and patients were receiving an initial dose of
3.125 mg of carvedilol or placebo twice daily for 2 weeks with
doubling the dose every 2 weeks with target dose 25 mg of
carvedilol or placebo twice daily. The most important differ-
ence between COPERNICUS and CIBIS-ELD trials patients
populations is that in COPERNICUS study total 100% of
subjects were in NYHA class IV at baseline. In the Metoprolol
CR/XL Randomized Intervention Trial in Congestive Heart
Failure (MERIT-HF), large proportions of subjects were reach-
ing target metoprolol dose (64% on metoprolol but 82% on
placebo), mean age of the cohort being 64 years. The starting
dose was 25 mg of metoprolol CR/XL or placebo once daily
(12.5 mg in NYHA III or IV) with doubling the dose every
2 weeks to reach target 200 mg once daily [4]. High tolerability
of betablocker therapy in elderly heart failure patients was
reported in the Study of Effects of Nebivolol Intervention and
Outcomes and Rehospitalization in Senior with Heart Failure
(The SENIORS Study) [6]. Nebivolol is a beta1-selective adre-
noreceptor blocker with vasodilatory effect not dependent of
alfa1-receptor blockade [11]. Efﬁcacy, tolerability and safety
of nebivolol were tested in several studies. In the Efﬁcacy of
Nebivolol in the treatment of Elderly patients with chronic
heart failure as add-on therapy (the ENECA) study 260 CHF
patients older than 65 years were randomized to nebivolol or
placebo [12]. The primary objective of the ENECA study was
the change of LV EF, the secondary objective included other
efﬁcacy endpoints and tolerability and safety of nebivolol.
Titration of nebivolol or placebo started with 1.25 mg and the
dose was doubled every 2 weeks until the highest tolerated
dose was reached or a maximum of 10 mg after 8 weeks (daily
dose). The LVEF improved signiﬁcantly more in the nebivolol
group than in the placebo group (p¼0.027) and the relative
improvement was higher in the nebivolol group than in the
placebo group (p¼0.008) as assessed by echocardiography.
Nebivolol was well tolerated in the elderly patients with
chronic heart failure. Severe averse events were less frequent
in the nebivolol group than in the placebo group (12% vs. 15%).
Drug-related averse events were more frequent in the nebivo-
lol group and included bradycardia events, hypotension and
dizziness. Worsening heart failure, ventricular tachycardia
and new onset atrial ﬁbrillation were less frequent in the
nebivolol group; the difference was not statistically signiﬁcant.Effect of nebivolol on mortality in elderly patients
with chronic heart failure
The SENIORS study aimed to assess the effects of nebivolol in
patients 70 years and older [6]. The primary objective was to
determine the effect of nebivolol on mortality and morbidity
regardless of ejection fraction. The study was a parallel
group, randomized, double-blind, multicentre, international
trial. Patients 70 years and older with a history of CHF and
one of the following features: documented hospital admis-
sion within the last 12 months before entry to the study or LV
EFr35% within previous 6 months were included in the trial.
Stable medical therapy more than 6 weeks and no change in
the cardiovascular therapy within 2 weeks before randomiza-
tion were required in all subjects. Patients were randomly
assigned to nebivolol or placebo on a 1:1 basis. The initial
dose was 1.25 mg with increasing the dose when tolerated to
2.5 mg and then to 5 mg every 1–2 weeks with a target dose of
10 mg over 16 weeks as a maximum. The primary objective of
the SENIORS study was the composite of all cause mortality
and cardiovascular hospital admission. Secondary endpoints
included all cause mortality, all cause hospital admissions,
cardiovascular mortality, and others. A total of 2135 patients
were included in the study (1067 in the nebivolol group and
1061 in the placebo group were available for analysis) and
followed from September 2000 to November 2003. Mean age
of the SENIORS trial population was 76.1 years, NYHA classes
II and III were most common (56% and 39%, respectively) at
baseline, and mean LV EF was 36% (median 33% in the
nebivolol group and 34% in the placebo group), 64% of
subjects had LVEFr35% and 36% of patients had LV
EF435%. From total 2128 patients at the end of the study,
of the 65% subjects in the nebivolol group were on drug and
of 64.2% patients in placebo group were on drug. The dose
Z5 mg was achieved in 80% of patients in the nebivolol group
and in 87% of subjects in the placebo group. The target
betablocker dose 10 mg daily was used in 68% of patients in
the nebivolol group (68% of 65% on nebivolol at the end of the
study) and 80% in the placebo group (80% of 64.2% on placebo
at the end of the study). The effect of nebivolol on the
primary endpoint was signiﬁcant. The relative risk of death
or cardiovascular hospital admission was reduced with nebi-
volol by 14% (hazard ratio 0.86, p¼0.039). There was no
statistical signiﬁcant effect of nebivolol on all cause mortality
and cardiovascular hospital admissions as an individual
endpoint observed in the SENIORS study. In conclusion, the
SENIORS study showed a positive effect of nebivolol on the
reduction of the composite endpoint mortality and hospital
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CHF. One-third of the SENIORS population had LV EF435%,
50% were 75 years and older and 37% of patients were
women. Beneﬁcial effect of nebivolol started 6 months after
the beginning of treatment, the study medication was extre-
mely well tolerated with 68% of patients achieving target
betablocker dose [13]. The high tolerability of nebivolol in the
elderly patients with chronic heart failure might be explained
by its unique pharmacological properties.Clinical pharmacology of nebivolol
Based on the results of the large randomized, placebo-
controlled interventional mortality trials, European guide-
lines for the management of chronic heart failure recom-
mends four: carvedilol, bisoprolol, metoprolol succinate
(controlled released) and nebivolol. Carvedilol is the non-
selective α1–β1–β2 adrenoreceptor blocker betablockers with
antiproliferative and antioxidant properties. Metoprolol suc-
cinate CR/XL is the selective β1-adrenoreceptor blocker with-
out important additional properties. Bisoprolol is the
selective β1-adrenoreceptor blocker with higher selectivity to
β1-receptor than metoprolol. Higher selectivity of bisoprolol
might explain more bradycardia events as reported in the
CIBIS-ELD study. Nebivolol is a beta-1 selective blocker with
vasodilating properties. Nebivolol is a racemic mixture of two
enantiomers with a highly selective beta-1-blocking activity
and without an intrinsic sympathomimetic activity. Nebivolol
has a unique haemodynamic and therapeutic proﬁle, which
is advantageous in essential hypertension, ischemic heart
disease and congestive heart failure. Nebivolol does not
compromise the left ventricular function; it increases stroke
volume and does not have negative inotropic effect during
exertion [11]. The vasodilating effect of nebivolol is not
dependent on alfa-1-adrenoreceptor blockade, which usually
produces symptomatic hypotension and postural drop in
blood pressure mainly in the elderly patients. The vasodilat-
ing effect of nebivolol is explained by the inhibition of nitric
oxide degradation. Nebivolol was ﬁrst tested as an effective
antihypertensive drug. The positive effect of nebivolol in
chronic heart failure might be explained by the reduction of
neurohormonal sympathetic activation, reduction of wall
stress, reduction in heart rate with improved coronary perfu-
sion, and reduction of incident coronary events. High toler-
ability of nebivolol in the elderly with a low frequency of
adverse events might be explained by its high beta-1 selec-
tivity (and low incidence of side effects usually reported in
non-selective drugs, e.g. pulmonary events) and vasodilating
properties providing peripheral tissue perfusion without
rapid decrease of arterial pressure.Conclusion
Several studies and surveys have shown that the use and
dose of betablockers in CHF patients is not often optimal [14].
The underuse and underdose of betablockers are particularly
evident in elderly patients [8]. Results from the CIBIS-ELD
study showed that titration of BBs to target in elderly heartfailure patients may be more difﬁcult [10]. Not reaching target
dose for carvedilol in the elderly heart failure subjects might
be also explained by the strict recommendation of the
previous guidelines recommending the target for carvedilol
50 mg bid for subjects weighting 85 kg and above [15]. Current
guidelines do not mention weight dependence carvedilol
dose with target dose range 25–50 mg bid [7].
High tolerability was reported for nebivolol in the SENIORS
study [6,13]. Elderly patients are at a higher risk of side effects
of BBs (mainly hypotension, bradycardia and pulmonary
events); nevertheless, 68% of patients reached the target dose
in the nebivolol group (68% of 65% on the drug at the end of
the study). High tolerability of nebivolol in older patients with
CHFmight be explained by its pharmacological properties [11,12].
Several factors limit the use and dose of BBs in elderly
patients with chronic heart failure, mainly the presence of
comorbidities associated with relative contraindication to BBs
therapy: chronic obstructive pulmonary disease, peripheral
artery disease and the risk of postural hypotension and
associated neurologic disorders. So, β1-adrenoreceptor block-
ers are the drug of choice in elderly patients with systolic
CHF. Another factor leading to the underuse of BBs in older
heart failure patients is the high prevalence of heart failure
with preserved ejection fraction in the elderly (HF PEF). And
there is lack of evidence of BBs beneﬁt in HF PEF.Conﬂict of interest
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